PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy

Tamara Lotan, Filipe Lf Carvalho, Sarah B. Peskoe, Jessica L. Hicks, Jennifer Good, Helen L. Fedor, Elizabeth Humphreys, Misop Han, Elizabeth A Platz, Jeremy A. Squire, Angelo Michael Demarzo, David M. Berman

Research output: Contribution to journalArticle

Abstract

When distinguishing between indolent and potentially harmful prostate cancers, the Gleason score is the most important variable, but may be inaccurate in biopsies due to tumor under-sampling. This study investigated whether a molecular feature, PTEN protein loss, could help identify which Gleason score 6 tumors on biopsy are likely to be upgraded at radical prostatectomy. Seventy one patients with Gleason score 6 tumors on biopsy upgraded to Gleason score 7 or higher at prostatectomy (cases) were compared with 103 patients with Gleason score 6 on both biopsy and prostatectomy (controls). A validated immunohistochemical assay for PTEN was performed, followed by fluorescence in situ hybridization (FISH) to detect PTEN gene deletion in a subset. PTEN protein loss and clinical-pathologic variables were assessed by logistic regression. Upgraded patients were older than controls (61.8 vs 59.3 years), had higher pre-operative PSA levels (6.5 vs 5.3 ng/ml) and a higher fraction of involved cores (0.42 vs 0.36). PTEN loss by immunohistochemistry was found in 18% (13/71) of upgraded cases compared with 7% (7/103) of controls (P=0.02). Comparison between PTEN immunohistochemistry and PTEN FISH showed the assays were highly concordant, with 97% (65/67) of evaluated biopsies with intact PTEN protein lacking PTEN gene deletion, and 81% (13/16) of the biopsies with PTEN protein loss showing homozygous PTEN gene deletion. Tumors with PTEN protein loss were more likely to be upgraded at radical prostatectomy than those without loss, even after adjusting for age, preoperative PSA, clinical stage and race (odds ratio=3.04 (1.08-8.55; P=0.035)). PTEN loss in Gleason score 6 biopsies identifies a subset of prostate tumors at increased risk of upgrading at radical prostatectomy. These data provide evidence that a genetic event can improve Gleason score accuracy and highlight a path toward the clinical use of molecular markers to augment pathologic grading.

Original languageEnglish (US)
Pages (from-to)128-137
Number of pages10
JournalModern Pathology
Volume28
Issue number1
DOIs
StatePublished - Jan 10 2015

Fingerprint

Neoplasm Grading
Prostatectomy
PTEN Phosphohydrolase
Prostatic Neoplasms
Biopsy
Gene Deletion
Neoplasms
Fluorescence In Situ Hybridization
Immunohistochemistry
Critical Pathways
Prostate
Logistic Models
Odds Ratio

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Lotan, T., Carvalho, F. L., Peskoe, S. B., Hicks, J. L., Good, J., Fedor, H. L., ... Berman, D. M. (2015). PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. Modern Pathology, 28(1), 128-137. https://doi.org/10.1038/modpathol.2014.85

PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. / Lotan, Tamara; Carvalho, Filipe Lf; Peskoe, Sarah B.; Hicks, Jessica L.; Good, Jennifer; Fedor, Helen L.; Humphreys, Elizabeth; Han, Misop; Platz, Elizabeth A; Squire, Jeremy A.; Demarzo, Angelo Michael; Berman, David M.

In: Modern Pathology, Vol. 28, No. 1, 10.01.2015, p. 128-137.

Research output: Contribution to journalArticle

Lotan, T, Carvalho, FL, Peskoe, SB, Hicks, JL, Good, J, Fedor, HL, Humphreys, E, Han, M, Platz, EA, Squire, JA, Demarzo, AM & Berman, DM 2015, 'PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy', Modern Pathology, vol. 28, no. 1, pp. 128-137. https://doi.org/10.1038/modpathol.2014.85
Lotan, Tamara ; Carvalho, Filipe Lf ; Peskoe, Sarah B. ; Hicks, Jessica L. ; Good, Jennifer ; Fedor, Helen L. ; Humphreys, Elizabeth ; Han, Misop ; Platz, Elizabeth A ; Squire, Jeremy A. ; Demarzo, Angelo Michael ; Berman, David M. / PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. In: Modern Pathology. 2015 ; Vol. 28, No. 1. pp. 128-137.
@article{ed7f0cb3b4ae403b803db32ce20617c9,
title = "PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy",
abstract = "When distinguishing between indolent and potentially harmful prostate cancers, the Gleason score is the most important variable, but may be inaccurate in biopsies due to tumor under-sampling. This study investigated whether a molecular feature, PTEN protein loss, could help identify which Gleason score 6 tumors on biopsy are likely to be upgraded at radical prostatectomy. Seventy one patients with Gleason score 6 tumors on biopsy upgraded to Gleason score 7 or higher at prostatectomy (cases) were compared with 103 patients with Gleason score 6 on both biopsy and prostatectomy (controls). A validated immunohistochemical assay for PTEN was performed, followed by fluorescence in situ hybridization (FISH) to detect PTEN gene deletion in a subset. PTEN protein loss and clinical-pathologic variables were assessed by logistic regression. Upgraded patients were older than controls (61.8 vs 59.3 years), had higher pre-operative PSA levels (6.5 vs 5.3 ng/ml) and a higher fraction of involved cores (0.42 vs 0.36). PTEN loss by immunohistochemistry was found in 18{\%} (13/71) of upgraded cases compared with 7{\%} (7/103) of controls (P=0.02). Comparison between PTEN immunohistochemistry and PTEN FISH showed the assays were highly concordant, with 97{\%} (65/67) of evaluated biopsies with intact PTEN protein lacking PTEN gene deletion, and 81{\%} (13/16) of the biopsies with PTEN protein loss showing homozygous PTEN gene deletion. Tumors with PTEN protein loss were more likely to be upgraded at radical prostatectomy than those without loss, even after adjusting for age, preoperative PSA, clinical stage and race (odds ratio=3.04 (1.08-8.55; P=0.035)). PTEN loss in Gleason score 6 biopsies identifies a subset of prostate tumors at increased risk of upgrading at radical prostatectomy. These data provide evidence that a genetic event can improve Gleason score accuracy and highlight a path toward the clinical use of molecular markers to augment pathologic grading.",
author = "Tamara Lotan and Carvalho, {Filipe Lf} and Peskoe, {Sarah B.} and Hicks, {Jessica L.} and Jennifer Good and Fedor, {Helen L.} and Elizabeth Humphreys and Misop Han and Platz, {Elizabeth A} and Squire, {Jeremy A.} and Demarzo, {Angelo Michael} and Berman, {David M.}",
year = "2015",
month = "1",
day = "10",
doi = "10.1038/modpathol.2014.85",
language = "English (US)",
volume = "28",
pages = "128--137",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy

AU - Lotan, Tamara

AU - Carvalho, Filipe Lf

AU - Peskoe, Sarah B.

AU - Hicks, Jessica L.

AU - Good, Jennifer

AU - Fedor, Helen L.

AU - Humphreys, Elizabeth

AU - Han, Misop

AU - Platz, Elizabeth A

AU - Squire, Jeremy A.

AU - Demarzo, Angelo Michael

AU - Berman, David M.

PY - 2015/1/10

Y1 - 2015/1/10

N2 - When distinguishing between indolent and potentially harmful prostate cancers, the Gleason score is the most important variable, but may be inaccurate in biopsies due to tumor under-sampling. This study investigated whether a molecular feature, PTEN protein loss, could help identify which Gleason score 6 tumors on biopsy are likely to be upgraded at radical prostatectomy. Seventy one patients with Gleason score 6 tumors on biopsy upgraded to Gleason score 7 or higher at prostatectomy (cases) were compared with 103 patients with Gleason score 6 on both biopsy and prostatectomy (controls). A validated immunohistochemical assay for PTEN was performed, followed by fluorescence in situ hybridization (FISH) to detect PTEN gene deletion in a subset. PTEN protein loss and clinical-pathologic variables were assessed by logistic regression. Upgraded patients were older than controls (61.8 vs 59.3 years), had higher pre-operative PSA levels (6.5 vs 5.3 ng/ml) and a higher fraction of involved cores (0.42 vs 0.36). PTEN loss by immunohistochemistry was found in 18% (13/71) of upgraded cases compared with 7% (7/103) of controls (P=0.02). Comparison between PTEN immunohistochemistry and PTEN FISH showed the assays were highly concordant, with 97% (65/67) of evaluated biopsies with intact PTEN protein lacking PTEN gene deletion, and 81% (13/16) of the biopsies with PTEN protein loss showing homozygous PTEN gene deletion. Tumors with PTEN protein loss were more likely to be upgraded at radical prostatectomy than those without loss, even after adjusting for age, preoperative PSA, clinical stage and race (odds ratio=3.04 (1.08-8.55; P=0.035)). PTEN loss in Gleason score 6 biopsies identifies a subset of prostate tumors at increased risk of upgrading at radical prostatectomy. These data provide evidence that a genetic event can improve Gleason score accuracy and highlight a path toward the clinical use of molecular markers to augment pathologic grading.

AB - When distinguishing between indolent and potentially harmful prostate cancers, the Gleason score is the most important variable, but may be inaccurate in biopsies due to tumor under-sampling. This study investigated whether a molecular feature, PTEN protein loss, could help identify which Gleason score 6 tumors on biopsy are likely to be upgraded at radical prostatectomy. Seventy one patients with Gleason score 6 tumors on biopsy upgraded to Gleason score 7 or higher at prostatectomy (cases) were compared with 103 patients with Gleason score 6 on both biopsy and prostatectomy (controls). A validated immunohistochemical assay for PTEN was performed, followed by fluorescence in situ hybridization (FISH) to detect PTEN gene deletion in a subset. PTEN protein loss and clinical-pathologic variables were assessed by logistic regression. Upgraded patients were older than controls (61.8 vs 59.3 years), had higher pre-operative PSA levels (6.5 vs 5.3 ng/ml) and a higher fraction of involved cores (0.42 vs 0.36). PTEN loss by immunohistochemistry was found in 18% (13/71) of upgraded cases compared with 7% (7/103) of controls (P=0.02). Comparison between PTEN immunohistochemistry and PTEN FISH showed the assays were highly concordant, with 97% (65/67) of evaluated biopsies with intact PTEN protein lacking PTEN gene deletion, and 81% (13/16) of the biopsies with PTEN protein loss showing homozygous PTEN gene deletion. Tumors with PTEN protein loss were more likely to be upgraded at radical prostatectomy than those without loss, even after adjusting for age, preoperative PSA, clinical stage and race (odds ratio=3.04 (1.08-8.55; P=0.035)). PTEN loss in Gleason score 6 biopsies identifies a subset of prostate tumors at increased risk of upgrading at radical prostatectomy. These data provide evidence that a genetic event can improve Gleason score accuracy and highlight a path toward the clinical use of molecular markers to augment pathologic grading.

UR - http://www.scopus.com/inward/record.url?scp=84920750150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920750150&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2014.85

DO - 10.1038/modpathol.2014.85

M3 - Article

C2 - 24993522

AN - SCOPUS:84920750150

VL - 28

SP - 128

EP - 137

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 1

ER -